Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
- PMID: 16529910
- DOI: 10.1016/j.schres.2005.10.016
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
Abstract
Background: Many patients recovering from a first psychotic episode will discontinue medication against medical advice, even before a 1-year treatment course is completed. Factors associated with treatment adherence in patients with chronic schizophrenia include beliefs about severity of illness and need for treatment, treatment with typical versus atypical antipsychotic and medication side effects.
Method: In this 2-year prospective study of 254 patients recovering from a first episode of schizophrenia, schizophreniform, or schizoaffective disorder we examined the relationship between antipsychotic medication non-adherence and patient beliefs about: need for treatment, antipsychotic medication benefits, and negative aspects of antipsychotic medication treatment. We also examined the relationship between medication non-adherence and treatment with either haloperidol or olanzapine, and objective measures of symptom response and side effects.
Results: The likelihood of becoming medication non-adherent for 1 week or longer was greater in subjects whose belief in need for treatment was less (HR=1.75, 95% CI 1.16, 2.65, p=0.0077) or who believed medications were of low benefit (HR=2.88, 95 CI 1.79-4.65, p<0.0001). Subjects randomized to haloperidol were more likely to become medication non-adherent for >or=1 week than subjects randomized to olanzapine (HR-1.51, 95% CI 1.01, 2.27, p=0.045).
Conclusion: Beliefs about need for treatment and the benefits of antipsychotic medication may be intervention targets to improve likelihood of long-term medication adherence in patients recovering from a first episode of schizophrenia, schizoaffective, or schizophreniform disorder.
Similar articles
-
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.Am J Psychiatry. 2004 Jun;161(6):985-95. doi: 10.1176/appi.ajp.161.6.985. Am J Psychiatry. 2004. PMID: 15169686 Clinical Trial.
-
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.J Clin Psychiatry. 2008 Jan;69(1):106-13. doi: 10.4088/jcp.v69n0114. J Clin Psychiatry. 2008. PMID: 18312044 Clinical Trial.
-
Olanzapine versus haloperidol treatment in first-episode psychosis.Am J Psychiatry. 1999 Jan;156(1):79-87. doi: 10.1176/ajp.156.1.79. Am J Psychiatry. 1999. PMID: 9892301 Clinical Trial.
-
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.J Psychopharmacol. 2010 Jul;24(7):1019-29. doi: 10.1177/0269881109348157. Epub 2009 Dec 14. J Psychopharmacol. 2010. PMID: 20008446 Review.
-
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Hum Psychopharmacol. 2011. PMID: 23055416 Review.
Cited by
-
Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.Front Psychiatry. 2022 Apr 28;13:877867. doi: 10.3389/fpsyt.2022.877867. eCollection 2022. Front Psychiatry. 2022. PMID: 35573364 Free PMC article.
-
A prospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis.Am J Psychiatry. 2011 Jul;168(7):742-8. doi: 10.1176/appi.ajp.2011.10071051. Epub 2011 Mar 31. Am J Psychiatry. 2011. PMID: 21454918 Free PMC article.
-
A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia.Schizophr Res. 2009 Sep;113(2-3):138-44. doi: 10.1016/j.schres.2009.04.018. Epub 2009 May 28. Schizophr Res. 2009. PMID: 19481424 Free PMC article.
-
Psychosocial Features of Clinically Relevant Patient Subgroups With Serious Mental Illness and Comorbid Diabetes.Psychiatr Serv. 2017 Jan 1;68(1):96-99. doi: 10.1176/appi.ps.201500554. Epub 2016 Sep 15. Psychiatr Serv. 2017. PMID: 27629797 Free PMC article. Clinical Trial.
-
A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.Clin Drug Investig. 2012 Nov;32(11):735-45. doi: 10.1007/s40261-012-0002-8. Clin Drug Investig. 2012. PMID: 23018281 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical